Why is Pfizer including clinical trials in its disclosure?
Pfizer believes that reporting clinical trial payments will help the public understand the full breadth of the important collaborative work done by industry, academia and health care professionals to advance health. Pfizer’s plans reflect the spirit of recently proposed legislation in that it includes payments to U.S. practicing physicians and other U.S. health care professionals for speaking and consulting, as well as to principal investigators and institutions for Phase I-IV clinical trials sponsored by Pfizer. Pfizer expects to report payments to major institutions for ongoing clinical trials and to principal investigators and all other entities for trials begun on or after July 1, 2009.
